Sastre Real, María, Díaz de Terán, Javier · Frontiers in neurology · 2020 · DOI
This study looked at whether a migraine treatment called botulinum toxin (Botox) could help people who have both chronic migraines and fibromyalgia. Researchers found that about two-thirds of patients improved within 3 months, and by 12 months, nearly 70% had at least a 50% reduction in severe headache days. The treatment was generally safe with only mild side effects.
This study is relevant to ME/CFS patients because nearly half of the fibromyalgia cohort also had ME/CFS, which are both central sensitization syndromes frequently comorbid with chronic migraine. The finding that botulinum toxin was effective in this multiply-affected population suggests potential benefits for the overlapping condition cluster, though ME/CFS-specific outcomes were not measured.
This study does not prove that botulinum toxin directly treats ME/CFS or other central sensitization syndromes—it only demonstrates efficacy for chronic migraine in patients who happen to have fibromyalgia. The observational design without controls cannot establish whether improvements were due to the treatment, placebo effect, or natural disease variation. The study excludes patients with fibromyalgia alone, so efficacy in non-migraine populations remains unknown.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →